Deutsche Bank Initiates Infinity Pharmaceuticals With Buy

Analysts at Deutsche Bank initiated coverage on

with a Buy rating. The target price for Infinity Pharmaceuticals is set to $20. Infinity Pharmaceuticals shares have gained 41.40 percent over the past 52 weeks, while the S&P 500 index has surged 10.90 percent in the same period. Infinity Pharmaceuticals' shares rose 1.15 to $12.30 in after-hours trading.